GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (OTCPK:ESALF) » Definitions » EV-to-EBITDA

Eisai Co (Eisai Co) EV-to-EBITDA

: 12.45 (As of Today)
View and export this data going back to . Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Eisai Co's enterprise value is $10,051 Mil. Eisai Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $807 Mil. Therefore, Eisai Co's EV-to-EBITDA for today is 12.45.

The historical rank and industry rank for Eisai Co's EV-to-EBITDA or its related term are showing as below:

ESALF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.27   Med: 5.3   Max: 61.28
Current: 12.45

During the past 13 years, the highest EV-to-EBITDA of Eisai Co was 61.28. The lowest was 2.27. And the median was 5.30.

ESALF's EV-to-EBITDA is ranked better than
54.11% of 706 companies
in the Drug Manufacturers industry
Industry Median: 13.805 vs ESALF: 12.45

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-19), Eisai Co's stock price is $38.95. Eisai Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $1.206. Therefore, Eisai Co's PE Ratio for today is 32.30.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Eisai Co EV-to-EBITDA Historical Data

The historical data trend for Eisai Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.99 13.06 22.28 15.16 23.30

Eisai Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.25 23.30 25.28 19.63 17.06

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eisai Co EV-to-EBITDA Distribution

For the Drug Manufacturers industry and Healthcare sector, Eisai Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Eisai Co's EV-to-EBITDA falls into.



Eisai Co EV-to-EBITDA Calculation

Eisai Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=10051.481/807.11
=12.45

Eisai Co's current Enterprise Value is $10,051 Mil.
Eisai Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $807 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eisai Co  (OTCPK:ESALF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Eisai Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=38.95/1.206
=32.30

Eisai Co's share price for today is $38.95.
Eisai Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.206.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Eisai Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Eisai Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Eisai Co (Eisai Co) Business Description

Traded in Other Exchanges
Address
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.